Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Endocrinology

What Is High-Risk vs. Very High-Risk Osteoporosis?

At a Glance

Very-high-risk osteoporosis means a substantially greater near-term fracture chance than high-risk osteoporosis. Recent or multiple fragility fractures, very low bone density, a high fracture estimate, treatment failure, or high fall risk may lead clinicians to consider a bone-building medicine first.

When you are diagnosed with osteoporosis, your doctor will determine your chance of experiencing a serious fracture in the next few years. Clinical guidelines, such as the 2020 American Association of Clinical Endocrinology (AACE) framework for postmenopausal osteoporosis, classify fracture risk into two main categories: high risk and very high risk [1].

The clinical difference between these two categories comes down to severity: “very high risk” means a patient has a substantially higher near-term chance of a fracture compared to someone with “high risk” osteoporosis [2]. This distinction helps your doctor evaluate whether to start treatment with a medication that slows bone loss, or an aggressive one that actively builds new bone [2].

How is “Very High Risk” Diagnosed?

Risk categories are a clinical framework, not just strict rules. While standard osteoporosis often places a patient at “high risk,” a clinician may categorize a patient as “very high risk” if they meet certain criteria. The AACE guidelines provide the following examples [1]:

  • Recent or multiple fractures: Having a fragility fracture (a broken bone from a minor bump or fall from standing height) recently, such as within the past 12 months, or suffering multiple fragility fractures [3].
  • Extremely low bone density: A dual-energy X-ray absorptiometry (DXA) scan showing a T-score (a measure comparing your bone density to a healthy young adult) of less than -3.0 at the lumbar spine (lower back) or total hip [4].
  • High FRAX probability: The FRAX tool estimates your 10-year chance of breaking a bone. The AACE uses a 10-year probability of over 30% for a major osteoporotic fracture (spine, hip, wrist, or upper arm) or over 4.5% for a hip fracture as very high-risk thresholds [4]. Note that these exact cutoffs can vary by country and guideline [5].
  • Failing past treatments: Suffering a new fracture despite taking osteoporosis medication for an adequate period [3].
  • High fall risk: A history of falls resulting in injury or being at a high risk for falling [6].

Patients who have osteoporosis and an elevated chance of fracture but do not meet these specific extreme criteria are generally considered “high risk.” Clinicians make this assessment by integrating age, bone density, FRAX scores, fall risk, and medication history (like steroid use) [1] [7].

What this might mean for a recent wrist fracture:
A wrist fracture from a simple trip and fall at standing height is a fragility fracture. Its exact date, combined with your DXA results and other clinical factors, helps your doctor determine if your current risk is “high” or “very high” under guidelines like AACE [3].

Treatment Options: Matching Intensity to Your Risk

Your risk category guides the initial choice of medication, but the decision is not automatic. Your treatment will be individualized based on your kidney function, cardiovascular history, ability to take certain medications, and personal preferences [2]. Regardless of the medication chosen, foundational steps like fall prevention, adequate calcium and vitamin D, and checking for secondary causes of osteoporosis are essential for all patients [1].

For High-Risk Patients:
Standard guidelines usually recommend starting with an antiresorptive medication [2]. These drugs slow down the cells that break down bone, allowing your body to maintain its current bone density. Options include weekly oral pills (bisphosphonates like alendronate) or injections/infusions (denosumab or zoledronic acid) [8].

For Very-High-Risk Patients:
Some bone-building medicines (anabolic agents) are favored for selected very-high-risk patients because they can increase bone density quickly and have strong fracture-reduction evidence [9] [10]. Medicines like teriparatide, abaloparatide, or romosozumab actively stimulate bone formation. Because bone-builders are only used for a limited time, transitioning to an antiresorptive medication afterward is generally recommended to help maintain the benefit and preserve the newly built bone [11] [12].

Comparing the Medications

Medicine Class Common Options How It is Taken Important Safety & Duration Notes
Antiresorptive Pill Alendronate, Risedronate Weekly or monthly pill Must be taken on an empty stomach with water; you must remain upright for a period afterward. May be unsuitable if you have esophageal or swallowing issues [2].
Antiresorptive Injection Denosumab Injection every 6 months Crucial: Should not be delayed or stopped without starting a follow-up treatment, as bone loss and the chance of spinal fractures can quickly rebound [13] [14].
Bone-Builder Teriparatide, Abaloparatide Daily injection Generally used for a maximum of around 2 years [15]. Has specific precautions regarding bone disorders, skeletal radiation, or abnormal calcium [10].
Bone-Builder Romosozumab Monthly injections Given for 12 months [16]. Carries a cardiovascular warning and may not be appropriate if you have had a recent heart attack or stroke [17].

(Note: Always review your full medical history with your doctor to find the safest option for you.)

Common questions in this guide

How is high-risk osteoporosis different from very-high-risk osteoporosis?
Both categories mean a person has an elevated chance of a fracture. Very-high-risk osteoporosis indicates a substantially greater near-term fracture risk and may lead a clinician to consider a bone-building medicine, while high-risk patients often begin with an antiresorptive medicine.
Can a recent wrist fracture put me in the very-high-risk group?
A wrist fracture from a minor fall or a fall from standing height can be a fragility fracture and may support a very-high-risk classification, especially if it was recent or there have been multiple fractures. Your clinician also considers your bone-density scan, fracture-risk estimate, fall risk, and treatment history.
What DXA result is considered very high risk?
One AACE example is a T-score below -3.0 at the lower spine or total hip. This is not the only factor, and exact criteria can vary by guideline and country.
What FRAX result means very high fracture risk?
In the AACE framework described here, a 10-year FRAX probability above 30% for a major osteoporotic fracture or above 4.5% for a hip fracture is an example of very high risk. Cutoffs may differ in other countries or guidelines.
What treatment is usually considered for very-high-risk osteoporosis?
Selected very-high-risk patients may be offered a bone-building medicine such as teriparatide, abaloparatide, or romosozumab because these medicines can raise bone density quickly. Because use is limited, an antiresorptive medicine is generally started afterward to help preserve the benefit.
What is the usual starting treatment for high-risk osteoporosis?
Guidelines often recommend beginning with an antiresorptive medicine, such as alendronate, risedronate, denosumab, or zoledronic acid. The safest choice depends on kidney function, heart and blood-vessel history, digestive or swallowing problems, other medicines, and personal preferences.
Can I stop or delay denosumab if I feel well?
Denosumab should not be delayed or stopped without a planned follow-up treatment because bone loss and the risk of spinal fractures can rebound quickly. Ask your clinician for a transition plan before the next dose is due or before stopping treatment.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on osteoporosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my DXA scan and fracture history, do you consider my fracture risk to be high or very high?
  2. 2.Why do you recommend this specific drug for me over the other options?
  3. 3.What are the major side effects I should watch for, and what happens if I cannot tolerate this medication?
  4. 4.Do I need blood tests for vitamin D deficiency, calcium problems, or other secondary causes of osteoporosis before we begin?
  5. 5.If we start with a bone-builder or denosumab, what is our exact plan for when it is time to stop or transition?

References

References (17)
  1. 1

    AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.

    Camacho PM, Petak SM, Binkley N, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(Suppl 1)):1-46 doi:10.4158/GL-2020-0524SUPPL.

    PMID: 32427503
  2. 2

    Osteoporosis: Common Questions and Answers.

    Harris K, Zagar CA, Lawrence KV

    American family physician 2023; (107(3)):238-246.

    PMID: 36920813
  3. 3

    Recommendations for the optimal use of bone forming agents in osteoporosis.

    Veronese N, Briot K, Guañabens N, et al.

    Aging clinical and experimental research 2024; (36(1)):167 doi:10.1007/s40520-024-02826-3.

    PMID: 39120740
  4. 4

    Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.

    McClung MR, Betah D, Deignan C, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2023; (29(9)):716-722 doi:10.1016/j.eprac.2023.06.011.

    PMID: 37406858
  5. 5

    Bone Mineral Density: Clinical Relevance and Quantitative Assessment.

    Haseltine KN, Chukir T, Smith PJ, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021; (62(4)):446-454 doi:10.2967/jnumed.120.256180.

    PMID: 33310738
  6. 6

    Real-World Management of Patients With Osteoporosis at Very High Risk of Fracture.

    Diffenderfer BW, Wang Y, Pearman L, et al.

    The Journal of the American Academy of Orthopaedic Surgeons 2023; (31(6)):e327-e335 doi:10.5435/JAAOS-D-22-00476.

    PMID: 36791248
  7. 7

    Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis.

    Park SY, Gong HS, Kim KM, et al.

    Journal of bone metabolism 2018; (25(4)):195-211 doi:10.11005/jbm.2018.25.4.195.

    PMID: 30574464
  8. 8

    Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.

    Conley RB, Adib G, Adler RA, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2020; (35(1)):36-52 doi:10.1002/jbmr.3877.

    PMID: 31538675
  9. 9

    Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO).

    Silva BC, Madeira M, d'Alva CB, et al.

    Archives of endocrinology and metabolism 2022; (66(5)):591-603.

    PMID: 36191263
  10. 10

    Anabolic therapy for osteoporosis: update on efficacy and safety.

    Bandeira L, Lewiecki EM

    Archives of endocrinology and metabolism 2022; (66(5)):707-716.

    PMID: 36382760
  11. 11

    New Frontiers in Osteoporosis Therapy.

    Cheng C, Wentworth K, Shoback DM

    Annual review of medicine 2020; (71()):277-288 doi:10.1146/annurev-med-052218-020620.

    PMID: 31509477
  12. 12

    Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.

    Langdahl B

    Bone 2020; (139()):115516 doi:10.1016/j.bone.2020.115516.

    PMID: 32622871
  13. 13

    Prevention and Management of Denosumab Discontinuation Rebound Fractures.

    Jain S

    Endocrinology and metabolism clinics of North America 2024; (53(4)):559-583 doi:10.1016/j.ecl.2024.08.002.

    PMID: 39448137
  14. 14

    Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab.

    Betella N, Biamonte E, Matarazzo C, et al.

    Minerva endocrinologica 2020; (45(3)):165-171 doi:10.23736/S0391-1977.20.03137-5.

    PMID: 32186164
  15. 15

    Current Status of Bone-Forming Therapies for the Management of Osteoporosis.

    Sølling ASK, Harsløf T, Langdahl B

    Drugs & aging 2019; (36(7)):625-638 doi:10.1007/s40266-019-00675-8.

    PMID: 31066015
  16. 16

    Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis.

    Prather C, Adams E, Zentgraf W

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2020; (77(23)):1949-1956 doi:10.1093/ajhp/zxaa285.

    PMID: 32880646
  17. 17

    Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.

    Seeto AH, Tadrous M, Gebre AK, et al.

    Bone 2023; (167()):116610 doi:10.1016/j.bone.2022.116610.

    PMID: 36372197

This page is for informational purposes only and does not constitute medical advice. It explains osteoporosis risk categories, but your clinician must interpret your DXA results, fracture history, and medical history when recommending treatment.